C-Phycocyan in the Prevention and Treatment of COVID-19: A Possibility Based on In silico Evidences
Coronavirus disease (COVID-19) is responsible for the current pandemic that worries the world. C-Phycocyanin (C-PC) appears as an attractive alternative for the prevention and treatment of COVID-19 due to its diverse biological activities. We perform protein-protein (P-P) docking with the PRISM webserver for evaluate the interaction of C-PC (in its complete form or just its F chain) with ACE2 (human cell receptor) and with viral proteins that participate in the onset and development of the infection. The F chain interacted with the ACE2 receptor (in vivo, C-PC may prevent the virus fusing with human cells) and with several viral proteins fundamental to infection and replication (in vivo, C-PC may block viral replication). Our results encourage the development of new studies for the use of C-PC as an anti-SARS-CoV-2 drug.